🧬 AI-Powered Drug Discovery

Sentinus.AI®

Transforming Drug Discovery for Cancer Therapeutics, Metabolic Diseases, Companion Diagnostics & Infectious Disease

A boosted virtual B cell with the capacity to screen 10 billion antibody sequences and select your best options (affinity, toxicity, efficacy) in hours, not months.

Schedule a Demo Explore Products
10,000×
More Efficient
vs. Google AlphaFold AI
80%
Lower Cost
vs. traditional methods
40%
Wet-Lab Hit Rate
vs. industry avg. 2–5%
$350B+
Market Opportunity
therapeutics + CDx

Key Performance Highlights

De Novo Design Excellence

  • • 9.8% hit rate at round 1 zero-shot prediction
  • • 35% hit rate at round 2 iteration
  • • 50% overall success rate without structure information

Affinity Maturation Leadership

  • • Industry-leading 85.7% success rate (42 projects)
  • • 21.5% hit rate reduces wet lab tests
  • • 43.8% hit rate at round 2
  • • Dozens to thousands fold affinity improvements
  • • Picomolar potencies achieved

Competitive Advantage

10,000x cost reduction vs traditional 3D modeling. No structure dependence.

Quantifiable, reproducible success rates since 2021 translate directly to commercial viability—unlike competitors reporting qualitative "single-digit nanomolar" results.

How It Works

AI-Powered Drug Discovery Pipeline

From target identification to validated candidates in weeks, not years

🎯

Target Identification

AI screens entire proteome to identify optimal drug targets

→
🧬

Antibody Design

Screen 10 billion sequences computationally in hours

→
🔬

In Silico Validation

Predict binding affinity, toxicity, and efficacy

→
✅

Wet-Lab Confirmation

40% hit rate vs. industry 2-5%

Our Expertise

Targeting Complex Biological Pathways

Oncology Pathway

Cancer Therapeutics

Targeting tumor-specific antigens with precision-designed antibodies

Immune Pathway

Immuno-Oncology

Modulating immune checkpoints for enhanced anti-tumor response

Infectious Disease - Virus

Infectious Disease

Rapid antibody design for emerging pathogens and pandemic response

Metabolic Diseases

Metabolic Diseases

Novel biologics targeting metabolic pathways for diabetes, obesity, and related conditions

Recognition

Awards & Publications

🏆

Merck Pandemic Preparedness Award

Recognized for breakthrough work in rapid antibody design for emerging infectious diseases.

🔬

Gates Foundation Heritage

Core technology developed through global health initiatives tackling infectious disease.

📄

Nature Scientific Reports

Peer-reviewed publication with independent validation of our AI-designed antibody results.

Read Paper →
Trusted By

Leading Organizations

60+
Validated Projects
20+
Fee-for-Service Contracts
100+
Pipeline Engagements

Ready to Transform Drug Discovery?

Join Pfizer, Bayer, Yale, and 60+ organizations using Sentinus.AI

Contact Us Today